Humana Inc. Q3 FY2026 Earnings Call Summary
HUM
NYSE
Healthcare
📅 2026-11-06
⏱ ~60 sec read
🟡 Neutral
⏱️ 60-Second Brief
Humana Inc. · Q3 FY2026
Revenue
$41.16B
AI Sentiment
🟡 Neutral
While strong revenue growth and raised guidance are positive…
📌 Bottom Line:
Humana reported robust third-quarter revenue growth of 26.1% year-over-year to $41.16 billion, alongside a GAAP EPS of $1.33 but an Adjusted loss per share of $0.70. Despite the adjusted loss, the company raised its full…
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Humana reported robust third-quarter revenue growth of 26.1% year-over-year to $41.16 billion, alongside a GAAP EPS of $1.33 but an Adjusted loss per share of $0.70. Despite the adjusted loss, the company raised its full-year 2026 Adjusted EPS guidance, signaling confidence in its strategic growth initiatives and operational efficiency.
📊 Key Financial Metrics
Revenue
$41.16B
EPS (Diluted)
—
YoY Revenue Growth
26.1%
AI Sentiment
🟡 Neutral
While strong revenue growth and raised guidance are positive, the quarterly adjusted loss and the acknowledged Star Ratings headwind introduce significant complexities and risks, balancing the overall outlook.
✅ What Went Well
**Robust Revenue Growth:** Humana delivered impressive consolidated revenues of $41.16 billion for the third quarter of 2026, representing a significant 26.1% increase compared to the same period last year. This strong top-line performance indicates healthy demand for its services and successful market penetration across its diverse healthcare offerings.
**Raised Full-Year Adjusted EPS Guidance:** Despite reporting an Adjusted loss per share for the quarter, the company demonstrated confidence in its future performance by raising its full-year 2026 Adjusted EPS guidance to 'at least $9.50', up from the prior expectation of 'at least $9.00'. This upward revision signals management's belief in sustained operational improvements and strategic execution, providing a more optimistic outlook for the fiscal year.
**Favorable Benefit Ratio:** The Insurance segment reported a GAAP benefit ratio of 93.7 percent, which was better than management's guidance of 'slightly above 94 percent'. This indicates effective management of healthcare costs and improved underwriting performance within its core insurance business, contributing to operational efficiency and potentially higher margins.
**Strong Strategic Segment Expansion:** Humana continues to expand its CenterWell and Medicaid footprints, showing significant membership growth. CenterWell Senior Primary Care saw a year-to-date growth of 146,800 patients, or 30 percent, while Medicaid membership grew by 103,600, or 7 percent, largely driven by new integrated Duals programs in key states like Michigan, Illinois, and South Carolina. This expansion underscores the success of its integrated care delivery model and its ability to capture market share in critical healthcare segments.
**Enhanced Financial Flexibility through BlackRock JV:** The recently announced joint venture with BlackRock for CenterWell Senior Primary Care is a strategic move designed to replace previous JVs, thereby enhancing balance sheet efficiency and providing greater financial flexibility. This partnership is expected to reduce the cost of capital and secure funding for future growth initiatives, strengthening Humana's long-term financial position and capacity for investment.
⚠️ Concerns & Risks
**Quarterly Adjusted Loss Per Share:** A primary concern is the reported Adjusted loss per share of $0.70 for 3Q26, a significant decline from an Adjusted EPS of $3.24 in 3Q25. While the company provides extensive non-GAAP adjustments, this quarterly adjusted loss could signal underlying pressures or substantial one-time costs impacting core profitability, requiring careful scrutiny by investors to understand the true operational picture.
**Impact of Star Ratings Headwind:** Management explicitly stated that the FY 2026 Adjusted EPS guidance anticipates a year-over-year decline due to the Star Ratings headwind for Bonus Year 2026, net of mitigation. The decline in Medicare Advantage plan ratings could negatively impact quality bonus payments from CMS and significantly affect future revenues, operating results, and cash flows, posing a material risk to profitability in a key business segment.
**Complexity of Non-GAAP Adjustments:** The extensive list of non-GAAP adjustments, including 'Put/call valuation adjustments associated with the company’s non-consolidating minority interest investments' and 'Value creation initiatives,' makes it challenging for investors to fully understand the company's true underlying operational performance. The magnitude of these adjustments, particularly the ($2.94) impact from put/call valuation adjustments on 3Q26 EPS, can obscure core business trends and make period-over-period comparisons difficult.
**Actuarial Estimates and Benefit Expense Risk:** As highlighted in the cautionary statement, Humana's profitability is highly dependent on its ability to design and price products properly and accurately estimate benefit expenses. These estimates involve extensive judgment and have considerable inherent variability, meaning that if reserves are insufficient or medical cost trends are underestimated, the company's profitability could be materially adversely affected, introducing financial uncertainty.
**Government Contractor Risks and Regulatory Changes:** Being a government contractor exposes Humana to risks such as potential inadequacy of government-determined payment rates, restrictions on profitability, and changes to the risk-adjustment model utilized by CMS. New laws or regulations, or changes in existing ones, could increase the company's cost of doing business, restrict revenue growth, and negatively impact financial position and cash flows, as detailed in the cautionary statement, creating an unpredictable operating environment.
🔮 CEO / Management Guidance
Humana revised its GAAP EPS guidance for the full year 2026 to 'at least $15.09', a substantial increase from the previous 'at least $6.52'. Concurrently, the company raised its Adjusted EPS guidance to 'at least $9.50' from the prior expectation of 'at least $9.00', though it anticipates a year-over-year decline in Adjusted EPS for FY 2026 due to the Star Ratings headwind, net of mitigation.
💬 Key Quote
Humana is delivering positive results for our members, our patients and their health. We are also increasingly driving financial and operating performance toward being 'ahead' of our plan. — Jim Rechtin, President and CEO
📅 Quarter-over-Quarter Comparison
Comparing Q3 FY2026
vs Q2 FY2026
All quarters →
Revenue
$40.888B
→
$41.16B
YoY Growth
26.24%
→
26.1%
Sentiment
🟡 Neutral
→
🟡 Neutral
🏢 About Humana Inc.
Humana Inc. (HUM) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Healthcare Services
Managed Care
Medicare Advantage
Medicaid Expansion
Strategic Partnerships
📁 More from Humana Inc.
View all earnings summaries for Humana Inc. →